There have also been clinical trials evaluating the use of disitamab vedotin in breast cancers, two of which were evaluated in a pooled analysis, showing efficacy in HER2-positive- and HER2-low-expressing subgroups [177]. Here, ERBB2 is linked to breast carcinoma.